文献速递肿瘤 PET/CT骨显像与常规 SPECT

在炎性关节炎出现临床疾病征象前无创PET检测CD69阳性免疫细胞

Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis.
PubMed 文献 · J Nucl Med · 2024-02-01

本研究在KRN T细胞转染炎性关节炎小鼠模型中评估CD69靶向PET示踪剂[68Ga]Ga-DOTA-ZCAM241的早期检测性能。结果显示,关节摄取在诱导后第3天即升高,早于第5-7天出现的临床症状,且摄取与临床评分及疾病严重程度相关,关节和淋巴结中CD69阳性细胞经流式细胞术和免疫染色证实。

要点

  • 在KRN T细胞转染关节炎模型中,[68Ga]Ga-DOTA-ZCAM241关节摄取在诱导后第3天升高,早于临床症状出现。
  • [68Ga]Ga-DOTA-ZCAM241摄取与临床评分及疾病严重程度相关。
  • 关节和淋巴结中CD69阳性细胞经流式细胞术和免疫染色证实。

核心结论

  • 在KRN T细胞转染炎性关节炎模型中,[68Ga]Ga-DOTA-ZCAM241在炎性关节的摄取早于临床症状出现,与CD69免疫染色结果一致。
  • [68Ga]Ga-DOTA-ZCAM241因此是类风湿关节炎起病期间组织内活化免疫细胞的一种有前景的PET显像标志物。

研究设计与样本

  • 通过将KRN T细胞受体转基因B6小鼠的脾细胞转移至T细胞缺陷的I-Ag7主要组织相容性复合体II类表达受体小鼠,诱导炎性关节炎模型。
  • 小鼠在关节炎诱导前及诱导后3、7、12天纵向接受[68Ga]Ga-DOTA-ZCAM241 PET/CT检查。
  • 通过测量体重和爪肿胀评分等临床参数监测疾病进展。
  • 分析爪部[68Ga]Ga-DOTA-ZCAM241摄取并以SUVmean表示,组织活检样本通过流式细胞术或免疫染色分析CD69表达。
  • 第二组小鼠使用不结合、大小匹配的Affibody分子作为对照进行检查。

主要发现

  • 临床症状在关节炎诱导后5-7天出现。
  • [68Ga]Ga-DOTA-ZCAM241在关节的摄取在基线时可忽略不计,但在疾病诱导后逐渐升高。
  • 在临床症状出现前的第3天即发现PET信号升高。
  • [68Ga]Ga-DOTA-ZCAM241摄取与临床评分和疾病严重程度相关。
  • 关节和淋巴结中CD69阳性细胞的存在经流式细胞术和免疫染色证实。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rheumatoid arthritis (RA) is the most common inflammatory joint disease, and early diagnosis is key for effective disease management. CD69 is one of the earliest cell surface markers seen at the surface of activated immune cells, and CD69 is upregulated in synovial tissue in patients with active RA. In this study, we evaluated the performance of a CD69-targeting PET agent, [68Ga]Ga-DOTA-ZCAM241, for early disease detection in a model of inflammatory arthritis. Methods: A model of inflammatory arthritis was induced by transferring splenocytes from KRN T-cell receptor transgenic B6 mice into T-cell-deficient I-Ag7 major histocompatibility complex class II-expressing recipient mice. The mice were examined longitudinally by [68Ga]Ga-DOTA-ZCAM241 PET/CT before and 3, 7, and 12 d after induction of arthritis. Disease progression was monitored by clinical parameters, including measuring body weight and scoring the swelling of the paws. The uptake of [68Ga]Ga-DOTA-ZCAM241 in the paws was analyzed and expressed as SUVmean Tissue biopsy samples were analyzed for CD69 expression by flow cytometry or immunostaining for a histologic correlate. A second group of mice was examined by a nonbinding, size-matched Affibody molecule as the control. Results: Clinical symptoms appeared 5-7 d after induction of arthritis. The uptake of [68Ga]Ga-DOTA-ZCAM241 in the joints was negligible at baseline but increased gradually after disease induction. An elevated PET signal was found on day 3, before the appearance of clinical symptoms. The uptake of [68Ga]Ga-DOTA-ZCAM241 correlated with the clinical score and disease severity. The presence of CD69-positive cells in the joints and lymph nodes was confirmed by flow cytometry and immunostaining. The uptake of the nonbinding tracer that was the negative control also increased gradually with disease progression, although to a lesser extent than with [68Ga]Ga-DOTA-ZCAM241 Conclusion: The uptake of [68Ga]Ga-DOTA-ZCAM241 in the inflamed joints preceded the clinical symptoms in the KRN T-cell transfer model of inflammatory arthritis, in accordance with immunostaining for CD69. [68Ga]Ga-DOTA-ZCAM241 is thus a promising PET imaging marker of activated immune cells in tissue during RA onset.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Puuvuori E, Shen Y, Hulsart-Billström G, et al. Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis. J Nucl Med. 2024. PMID: 38050119. doi:10.2967/jnumed.123.266336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。